Tandem Diabetes Care v Roche Diabetes Care (CFI, ORD_9062/2024, 20 February 2024)
| Date | 20 February 2024 |
|---|---|
| Court | CFI |
| Division | Paris (FR) Central Division - Seat |
| Type of action | Generic application |
| Registry reference | App_8392/2024 · ORD_9062/2024 |
| Parties | Roche Diabetes Care GmbH |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 20 February 2024 (UPC_CFI_455/2023), Paolo Catallozzi, judge-rapporteur of the Paris Central Division, hearing the action for a declaration of non-infringement of EP 2 196 231 brought on 30 November 2023 by Tandem Diabetes Care, Inc. and Tandem Diabetes Care Europe B.V. against Roche Diabetes Care GmbH, refused Roche’s request to extend the time limit for its Defence to 8 April 2024 or, in the alternative, 18 March 2024. The preliminary objection to jurisdiction lodged by Roche on 22 January 2024 does not suspend that time limit.
Question
Do a pending preliminary objection, the cost of pleadings that may prove unnecessary and the prospect of an infringement action leading to a stay (Rule 76.3) justify an extension under Rule 9.3 or a contrary decision under Rule 19.6?
Decision
No. Rule 9.3 confers a discretion to be exercised in line with proportionality, flexibility, fairness and equity (paragraphs 8 and 9), extensions are exceptional and require that compliance be objectively impossible or very difficult (paragraphs 16 and 17). Roche relied only on the possibility that its pleadings might prove useless (paragraph 18), the risk of a stay is irrelevant (paragraph 19). Rule 19.6, applicable through Rule 66, keeps the time limit for the Defence running despite the preliminary objection, unless the judge-rapporteur decides otherwise under the same requirements (paragraphs 20 to 23). The alleged need for clarity in relation to the parallel revocation action was not explained (paragraph 24).
Key points for practice
- Practical point: a party raising a preliminary objection must prepare its Defence within the normal time limit unless it shows an objective difficulty in meeting it (paragraphs 17 and 23).
Provisions applied
- Rules of Procedure
- Rules 9.3, 9.4, 19.6, 23, 66, 76.3 and 333
- Case law cited
- ITCiCo Spain, Paris Central Division, 9 February 2024, Paris Central Division, order of 10 November 2023, UPC_CFI_255/2023
Related decisions
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Written procedure (UPC), Court fees and costs (UPC).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimantRoche Diabetes Care GmbH14 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Generic application
- Outcome (Dhenne Avocats summary)
- Le juge rapporteur refuse de proroger le délai du mémoire en défense de Roche dans l'action en déclaration de non-contrefaçon, l'exception préliminaire pendante ne suspendant pas ce délai.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 2 196 231mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Tandem Diabetes Care v Roche Diabetes Care (CFI, ORD_9060/2024, 20 February 2024) cited in this record
- Bayerische Motoren Werke v ITCiCo Spain (CFI, 9 February 2024) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 2 196 231System for ambulatory drug infusion comprising a filling apparatus for flexible containers recorded proprietor: F Hoffmann La Roche AG et Roche Diagnostics GmbH | Mentioned in the analysis (role not qualified) Also mentioned in 9 other decision(s): Tandem Diabetes Care Europe v Roche Diabetes Care (CFI, 18 December 20 · Tandem Diabetes Care Europe v Roche Diabetes Care (CoA, 3 July 2025) · Tandem Diabetes Care Europe v Roche Diabetes Care (CoA, 5 June 2025) · Roche Diabetes Care v Tandem Diabetes Care (CFI, 9 September 2024) · Roche Diabetes Care v Tandem Diabetes Care (CFI, 26 July 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, 27 June 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, 10 May 2024) · Tandem Diabetes Care v Roche Diabetes Care (CFI, ORD_9060/2024, 20 Feb | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.